Stem cells possess remarkable potential to differentiate into various cell types, functioning as the body’s primary internal repair system.
The inherent capacity of stem cells to differentiate into specialized cell types (such as blood, brain, or tissue cells) replenishes and regenerates the body, countering the effects of aging and disease.
Hyperbaric oxygen therapy (HBOT) has been demonstrated to notably elevate the concentration of circulating stem/progenitor cells in the peripheral circulation system. This increase in blood plasma oxygen levels has been shown to significantly stimulate the proliferation and mobilization of bone marrow-derived stem cells. The proposed mechanism of action involves a nitric oxide-dependent pathway. This evidence is pivotal in regenerative medicine, as the heightened presence of stem cells in the body facilitates enhanced and accelerated physiological repair processes.
Research has shown the following therapeutic benefits of hyperbaric oxygen therapy on stem cells.
The information provided on this website is for educational purposes only and should not be viewed as a substitute for the diagnosis, treatment, or advice of a qualified licensed professional. This website offers general information and does not represent the practice of medicine. We do not take responsibility for how this information is utilized. Additionally, please note that the contents of this website are regularly updated for various reasons. Any statements or implied treatments have not been evaluated or approved by the FDA. It is crucial not to alter, discontinue, or change any medication or treatment without consulting your doctor first. Always seek your doctor’s advice before initiating any new treatment program.
The following research article underscores the benefits of hyperbaric oxygen therapy in stem cell treatments.
If you have inquiries regarding a particular symptom or condition, please don’t hesitate to reach out to us for assistance!
A seminal study published in 2005 (Am J Physiol Heart Circ Physiol Nov. 2005) examined 26 patients at risk for osteoradionecrosis following radiation therapy for head or neck tumors. All participants received twenty (20) HBOT sessions, with blood samples collected and analyzed after the first, tenth, and twentieth treatments. CD34 cell population in the peripheral circulation system doubled after the initial treatment and increased eight-fold by the trial’s conclusion. Colony-forming cells also notably increased, alongside elevated levels of vascular endothelial growth factor-2 and stromal-derived growth factor. The study concluded that HBOT mobilizes bone marrow-derived stem/progenitor cells by stimulating nitric oxide synthesis.
Learn about purchase and rental programs.
Copyright © 2024 Hyperbaric Hub LLC All Rights Reserved